NDC 61755-039

REGEN-COV

Casirivimab And Imdevimab

REGEN-COV is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Regeneron Pharmaceuticals, Inc.. The primary component is Casirivimab; Imdevimab.

Product ID61755-039_1b115152-c792-4dbd-aede-52dc7fdf8436
NDC61755-039
Product TypeHuman Prescription Drug
Proprietary NameREGEN-COV
Generic NameCasirivimab And Imdevimab
Dosage FormInjection, Solution, Concentrate
Route of AdministrationINTRAVENOUS
Marketing Start Date2021-06-03
Marketing CategoryUNAPPROVED DRUG OTHER /
Labeler NameRegeneron Pharmaceuticals, Inc.
Substance NameCASIRIVIMAB; IMDEVIMAB
Active Ingredient Strength600 mg/10mL; mg/10mL
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 61755-039-01

1 VIAL, GLASS in 1 CARTON (61755-039-01) > 10 mL in 1 VIAL, GLASS (61755-039-00)
Marketing Start Date2021-06-03
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "REGEN-COV" or generic name "Casirivimab And Imdevimab"

NDCBrand NameGeneric Name
61755-035REGEN-COVcasirivimab and imdevimab
61755-036REGEN-COVcasirivimab and imdevimab
61755-037REGEN-COVcasirivimab and imdevimab
61755-038REGEN-COVcasirivimab and imdevimab
61755-039REGEN-COVcasirivimab and imdevimab

Trademark Results [REGEN-COV]

Mark Image

Registration | Serial
Company
Trademark
Application Date
REGEN-COV
REGEN-COV
90284296 not registered Live/Pending
Regeneron Pharmaceuticals, Inc.
2020-10-28

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.